GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10$2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in$3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) Foster City, CA, April 25, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered ...